Kwality Pharmaceuticals Ltd
KPLKwality Pharmaceuticals Ltd's price has outrun its earnings. +158.2% in a year against EPS +69.0% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +158.2% in a year while annual EPS moved +69.0% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (24 weeks in) while the P/E sits at the 99th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +78.6% year on year, and 86% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Kwality Pharmaceuticals Ltd trades at ₹2,393, in a confirmed uptrend and 24 weeks into that stage. That is +75.1% against its own 200-day average. It sits at 100% of a 52-week range of ₹718 to ₹2,393. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 20 straight weeks.
Today the stock is in a confirmed uptrend — week 24 of stage 2, confirmed. At ₹2,393 it trades +75.1% versus its 200-day average and sits at 100% of its 52-week range (₹718–₹2,393).
Against the market, two honest reads. Cumulative: over the last 9.9 years the stock moved +10,537% while the NIFTY 500 moved +208% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 20 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 99th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Kwality Pharmaceuticals Ltd trades at 36.6× P/E, about the priciest it has ever traded. Its long-run median P/E is 14.5×, measured across 9.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 36.6× is about the priciest it has ever traded, against a long-run median of 14.5× measured over 9.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved +69.0% against a +158.2% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +87.1%/yr price move, ~+43.9%/yr came from earnings growth and ~+43.2 pp from the multiple (expanding); over 10y, of the +59.5%/yr price move, ~+53.5%/yr came from earnings growth and ~+6.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Consistent Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Kwality Pharmaceuticals Ltd reads as consistent on its fundamental arc. Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 31.1% and holding. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: steady curves with healthy returns are the compounding setup — the risk is the price, not the business.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +35.9% | +26.1% | +13.9% | +21.1% |
| Profit | +67.5% | +52.2% | +34.9% | +52.3% |
| EPS | +69.0% | +51.5% | +34.8% | +45.3% |
| Share price | +158.2% | +101.2% | +87.1% | +59.5% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
No sector-relative score — Kwality Pharmaceuticals Ltd is not present in the sector comparison for Pharma - Formulators.
The score is a rank WITHIN a peer set: every metric is scored by percentile against the other members. Without the peer set there is no score to state, so none is invented here.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Kwality Pharmaceuticals Ltd reported ₹157 Cr of revenue in the Mar 26 quarter, +35.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 21.1% a year. The last full year, FY26, came in at ₹503 Cr. The last four reported quarters add to ₹502 Cr.
Kwality Pharmaceuticals Ltd reported ₹157 Cr of revenue in the Mar 26 quarter, +35.3% year on year. That is the 11th straight quarter of year-on-year growth. Over 10 years it has compounded at 21.1% a year. The last full year, FY26, came in at ₹503 Cr. The last four reported quarters add to ₹502 Cr.
FY26 revenue came in at ₹503 Cr (+35.9% on the year), capping 10 years at 21.1% compound. The latest quarter (Mar 26) printed ₹157 Cr, +35.3% year on year — the 11th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +35.9% growth against the decade's 21.1% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +35.7% over the last 4 quarters against +27.9%/yr over the last 8 — accelerating; TTM profit +71.8% vs +70.7%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 25.0% this quarter (+3.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Kwality Pharmaceuticals Ltd's operating margin is 25.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 38.0%. The current quarter sits inside that band.
Kwality Pharmaceuticals Ltd's operating margin is 25.0% in the Mar 26 quarter, +3.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0% to 38.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 25.0%, +3.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0%–38.0%.
Why the margin moved: operating margin went +2.3 pp year on year while gross margin went −2.6 pp — the gain came mostly from the gross line: input costs and pricing.
→ Margins held — did that reach the bottom line? Next: profit +78.6% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Kwality Pharmaceuticals Ltd earned ₹25.0 Cr of net profit in the Mar 26 quarter, +78.6% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹67.0 Cr. The 10-year compound rate is 52.3%. That is 15.9% of the quarter's revenue. The same quarter a year earlier earned ₹14.0 Cr.
Kwality Pharmaceuticals Ltd earned ₹25.0 Cr of net profit in the Mar 26 quarter, +78.6% year on year. It is the 8th consecutive quarter of growth. Full-year FY26 profit was ₹67.0 Cr. The 10-year compound rate is 52.3%. That is 15.9% of the quarter's revenue. The same quarter a year earlier earned ₹14.0 Cr.
Mar 26 profit was ₹25.0 Cr, +78.6% year on year — the 8th consecutive quarter of growth. On the full year, FY26 printed ₹67.0 Cr (+67.5%), and the 10-year compound rate is 52.3%.
Why profit moved: revenue contributed +35.3% and the margin +3.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +70.3% vs revenue +35.9%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 86% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 86% of Kwality Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹17.0 Cr of operating cash against ₹67.0 Cr of profit. After ₹47.0 Cr of capital spending, ₹−30.0 Cr was left as free cash.
FY26: operating cash of ₹17.0 Cr against reported profit of ₹67.0 Cr, leaving free cash of ₹−30.0 Cr after ₹47.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 86% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 86%: the cash cycle stretched 140 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.7× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹97.0 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Kwality Pharmaceuticals Ltd's cash conversion cycle runs 170 days in FY26, up from 30 days in FY21. Capital spending ran ₹97.0 Cr over the last 3 years. At FY26 sales of ₹503 Cr each day of that cycle holds about ₹1.4 Cr, so roughly ₹234 Cr sits inside the business at any moment.
FY26: debtors at 203 days, inventory at 111 days — roughly 3.7 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 170 days, looser than FY21's 30.
The full loop: cash goes out to suppliers and production on day 0; stock waits 111 days to sell; customers pay about 203 days after that; and suppliers themselves are paid at 144 days — netting out to the 170-day cycle.
In money terms: at FY26 sales of ₹503 Cr, each day of the cycle holds about ₹1.4 Cr — so the 170-day loop keeps roughly ₹234 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹97.0 Cr over the last 3 fiscal years against ₹58.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹17.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 24% and the ROIC − WACC spread is +6.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Kwality Pharmaceuticals Ltd earns a ROCE of 24% in FY26. That is up from a trough of 9% in FY15. Return on invested capital clears the cost of that capital by +6.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 13.3% net margin on 0.85× asset turns.
FY26 ROCE is 24%, recovered from a FY15 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 13.3% net margin × 0.85× asset turns × 1.79× balance-sheet leverage ≈ 20.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 18.6% − 12.0% = a +6.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.39.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Kwality Pharmaceuticals Ltd carries total debt of ₹130 Cr against shareholder equity of ₹330 Cr as of Mar 26, a debt-to-equity of 0.39. On the annual view that ratio went from 0.35 in FY22 to 0.39 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹130 Cr against shareholder equity of ₹330 Cr — a debt-to-equity of 0.39. On the annual view, debt-to-equity went from 0.35 (FY22) to 0.39 (FY26). Read the returns on this page with that leverage in mind.
→ Who owns this, and are they adding or leaving? Next: Foreign institutions added 2.8 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 2.8 points of Kwality Pharmaceuticals Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 2.8% of the company. Domestic institutions moved +0.4 points over the same window, to 0.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +2.8 points over 8 quarters to 2.8%; Domestic institutions: +0.4 points over 8 quarters to 0.4%; Promoters: +0.0 points over 8 quarters to 54.9%.
Why the register moved: foreign institutions drove it (+2.8 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Kwality Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Kwality Pharmaceuticals Ltd this page | 36.6× | ₹2,483 Cr | Consistent | |||
| Sun Pharmaceutical Industries Ltd | 37.5× | ₹4.7L Cr | Improving | |||
| Torrent Pharmaceuticals Ltd | 86.1× | ₹1.9L Cr | Consistent | |||
| Cipla Ltd | 31.8× | ₹1.1L Cr | Deteriorating | |||
| Zydus Lifesciences Ltd | 20.4× | ₹1.1L Cr | Consistent | |||
| Lupin Ltd | 19.1× | ₹1.1L Cr | Consistent | |||
| Mankind Pharma Ltd | 51.4× | ₹1L Cr | Turning around | |||
| Dr Reddys Laboratories Ltd | 29.8× | ₹96,130 Cr | Deteriorating | |||
| Aurobindo Pharma Ltd | 25.1× | ₹88,979 Cr | Mixed | |||
| Biocon Ltd | 182.0× | ₹70,672 Cr | Deteriorating | |||
| Alkem Laboratories Ltd | 27.6× | ₹67,357 Cr | Mixed | |||
| Glenmark Pharmaceuticals Ltd | 21.0× | ₹61,858 Cr | No read | |||
| Ipca Laboratories Ltd | 37.9× | ₹44,720 Cr | Consistent | |||
| Ajanta Pharma Ltd | 37.3× | ₹42,097 Cr | Consistent | |||
| J B Chemicals & Pharmaceuticals Ltd | 53.8× | ₹38,677 Cr | Topping out | |||
| Emcure Pharmaceuticals Ltd | 37.7× | ₹35,679 Cr | Mixed | |||
| Wockhardt Ltd | 106.0× | ₹30,048 Cr | No read | |||
| Rubicon Research Ltd | 102.0× | ₹25,141 Cr | No read | |||
| ERIS Lifesciences Ltd | 30.7× | ₹19,409 Cr | Turning around | |||
| Caplin Point Laboratories Ltd | 29.2× | ₹18,753 Cr | Consistent | |||
| Natco Pharma Ltd | 11.6× | ₹16,504 Cr | Topping out | |||
| Alembic Pharmaceuticals Ltd | 21.4× | ₹15,678 Cr | Turning around | |||
| Corona Remedies Ltd | 64.7× | ₹12,923 Cr | No read | |||
| Marksans Pharma Ltd | 26.7× | ₹11,161 Cr | Consistent | |||
| Akums Drugs & Pharmaceuticals Ltd | 40.3× | ₹10,818 Cr | No read | |||
| Strides Pharma Science Ltd | 16.6× | ₹9,402 Cr | No read | |||
| Suven Life Sciences Ltd | — | ₹8,929 Cr | No read | |||
| FDC Ltd | 22.6× | ₹6,723 Cr | Turning around | |||
| Bliss GVS Pharma Ltd | 37.4× | ₹4,927 Cr | Turning around | |||
| RPG Life Sciences Ltd | 44.3× | ₹4,858 Cr | — | — | — | — |
| Gufic BioSciences Ltd | 59.2× | ₹3,799 Cr | No read | |||
| Kwality Pharmaceuticals Ltd | 42.5× | ₹2,886 Cr | Consistent | |||
| Sai Parenterals Ltd | 166.0× | ₹2,366 Cr | — | — | — | — |
| Indoco Remedies Ltd | — | ₹2,247 Cr | No read | |||
| Fredun Pharmaceuticals Ltd | 45.4× | ₹1,480 Cr | — | No read | ||
| Amrutanjan Health Care Ltd | 22.8× | ₹1,472 Cr | Mixed | |||
| Accent Microcell Ltd | 27.1× | ₹1,187 Cr | No read | |||
| Lincoln Pharmaceuticals Ltd | 13.2× | ₹1,162 Cr | Turning around | |||
| Bajaj Healthcare Ltd | 19.3× | ₹1,088 Cr | No read | |||
| Bharat Parenterals Ltd | — | ₹990 Cr | No read |
Frequently asked questions
What is Kwality Pharmaceuticals Ltd's share price today?
Kwality Pharmaceuticals Ltd trades at ₹2,393, +158.2% over the past year. The company is valued at ₹2,483 Cr. The stock sits at 100% of its 52-week range of ₹718–₹2,393, +75.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 24 weeks in. — as of 24 July 2026.
What were Kwality Pharmaceuticals Ltd's latest quarterly results?
Kwality Pharmaceuticals Ltd reported revenue of ₹157 Cr and net profit of ₹25.0 Cr for the Mar 26 quarter. Revenue rose 35.3% and profit rose 78.6% year on year. Earnings per share were ₹24.38. The operating margin was 25.0%, 3.0 pp higher than a year earlier. — as of 24 July 2026.
What is Kwality Pharmaceuticals Ltd's revenue?
Kwality Pharmaceuticals Ltd reported revenue of ₹157 Cr in the Mar 26 quarter, +35.3% year on year. For the full FY26 fiscal year, revenue was ₹503 Cr (+35.9%). Over the last 10 years revenue compounded at 21.1% a year. — as of 24 July 2026.
What is Kwality Pharmaceuticals Ltd's profit?
Kwality Pharmaceuticals Ltd earned ₹25.0 Cr of net profit in the Mar 26 quarter, +78.6% year on year — the 8th straight quarter of growth. Full-year FY26 profit was ₹67.0 Cr. The operating margin ran 25.0% in the latest quarter. — as of 24 July 2026.
What is Kwality Pharmaceuticals Ltd's market cap?
Kwality Pharmaceuticals Ltd's market capitalisation is ₹2,483 Cr at a share price of ₹2,393. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Kwality Pharmaceuticals Ltd's P/E ratio?
Kwality Pharmaceuticals Ltd trades at a P/E of 36.6×, at the 99th percentile of its own 10-year range, against a long-run median of 14.5×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Is Kwality Pharmaceuticals Ltd overvalued?
On its own history, Kwality Pharmaceuticals Ltd looks expensive against its own history: its P/E of 36.6× sits at the 99th percentile of its 10-year range (long-run median 14.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Kwality Pharmaceuticals Ltd growing?
Yes — Kwality Pharmaceuticals Ltd is growing: latest-quarter revenue +35.3% year on year, profit +78.6%, and the margin +3.0 pp at 25.0%. The 10-year compound rates are 21.1% (revenue) and 52.3% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Kwality Pharmaceuticals Ltd performing?
Kwality Pharmaceuticals Ltd is in a confirmed uptrend, 24 weeks in. Its latest quarter's revenue rose 35.3% and profit rose 78.6% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 20 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Kwality Pharmaceuticals Ltd in?
Consistent — revenue, profit and EPS growth have stayed positive through the window, with ROCE at 31.1% and holding. The read comes from the last 12 quarters of growth (revenue growth +35.7% latest, profit growth +71.8% latest, eps growth +69.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Kwality Pharmaceuticals Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 24 of stage 2), trading +75.1% versus its 200-day average and at 100% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Kwality Pharmaceuticals Ltd beating the market?
On recent form, yes — Kwality Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 20 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 9.9 years the stock moved +10,537% against the NIFTY 500's +208% — ahead of the index over the full window. — as of 24 July 2026.
Will Kwality Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Kwality Pharmaceuticals Ltd. What it measures instead: the share price is ₹2,393, the price is in a confirmed uptrend 24 weeks in. Its P/E of 36.6× sits at the 99th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Kwality Pharmaceuticals Ltd?
Promoters hold 54.9% of Kwality Pharmaceuticals Ltd, foreign institutions 2.8%, domestic institutions 0.4% and the public 42.0% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 2.8 points over 8 quarters. — as of 24 July 2026.
Does Kwality Pharmaceuticals Ltd have too much debt?
It is moderate — Kwality Pharmaceuticals Ltd's debt-to-equity is 0.39, and operating profit covers the interest bill 11×. FY26 borrowings were ₹130 Cr against equity of ₹331 Cr. Read the returns on this page with that leverage in mind — as of 24 July 2026.
What is Kwality Pharmaceuticals Ltd's capex?
Kwality Pharmaceuticals Ltd spent ₹97.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹47.0 Cr, with ₹17.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Kwality Pharmaceuticals Ltd's cash flow?
Kwality Pharmaceuticals Ltd generated ₹17.0 Cr of operating cash flow in FY26 and ₹−30.0 Cr of free cash flow after ₹47.0 Cr of capital spending. Reported profit that year was ₹67.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Kwality Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 86% of Kwality Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹17.0 Cr against reported profit of ₹67.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
Where is Kwality Pharmaceuticals Ltd in its business cycle?
Kwality Pharmaceuticals Ltd's FY26 operating margin was 24.0%, against a 13-year band of 6.0%–38.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 25.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Kwality Pharmaceuticals Ltd story?
The sharpest disagreement: the price moved +158.2% in a year while annual EPS moved +69.0% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Kwality Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Kwality Pharmaceuticals Ltd's price has outrun its earnings. +158.2% in a year against EPS +69.0% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.